Format

Send to

Choose Destination
Pneumologie. 2018 Feb;72(2):138-154. doi: 10.1055/s-0043-118904. Epub 2017 Dec 21.

[Updated Recommendation for Treatment of Metastatic Non-Small Cell Lung Cancer].

[Article in German; Abstract available in German from the publisher]

Author information

1
Asklepios Fachkliniken München-Gauting, Thorakale Onkologie, Gauting.
2
Clemenshospital Münster, Klinik für Pneumologie und Beatmungsmedizin, Münster.
3
Klinikverbund Kempten-Oberallgäu, Klinik für Pneumologie, Thoraxonkologie, Schlaf- und Beatmungsmedizin, Kempten.
4
Universitätsklinik Frankfurt, Klinik für Innere Medizin, Hämatologie und Onkologie, Frankfurt.
5
Universitätsklinikum Münster, Medizinische Klinik und Poliklinik A, Münster.
6
LungenClinic Grosshansdorf, Onkologischer Schwerpunkt, Airway Research Center North (ARCN), Deutsches Zentrum für Lungenforschung (DZL), Großhansdorf.

Abstract

in English, German

Lung cancer accounts for the leading cause of cancer deaths in Germany and is characterized by early metastasis formation. The majority of patients with non-small cell lung cancer (NSCLC) will receive systemic therapy for treatment of their disease. Importantly together with the identification of targetable oncogenic alterations, systemic treatment of NSCLC has dramatically changed in recent years with the implementation of various new agents such as tyrosine kinase inhibitors and immune modulating drugs. However, these new therapeutic options also challenge the treating physician since molecular, histologic, and clinical factors need to be considered for the clinical decisionmaking. Moreover, supportive therapy including bronchoscopic therapy has evolved. The following therapy recommendations will summarize the up-to date treatment strategies for metastatic NSCLC.

PMID:
29270953
DOI:
10.1055/s-0043-118904

Conflict of interest statement

N. Reinmuth: Honorare für Vorträge und Beratungstätigkeiten von Roche, Lilly, Novartis, MSD, BMS, Boehringer-Ingelheim, Astra-Zeneca, Pfizer.A. Gröschel: Honorare für Vorträge von Roche, BMS.C. Schumann: Honorare für Vorträge, Beratungen und Kongressreisen: Pfizer, Roche, BMS, Astra, Boehringer, Lilly.M. Sebastian: Honorare für Vorträge und Beratungstätigkeiten (Advisory Board) für AstraZeneca, BMS, Boehringer-Ingelheim, Celgene, MSD, Novartis, Pfizer, Roche, Merck, Lilly, Takeda.R. Wiewrodt: Honorare für Beratungen und Vorträge von Astra-Zeneca, Bayer, BMS, Boehringer-Ingelheim, Celgene, CSL, GSK, Hoffmann-La Roche, Lilly, MSD, Novartis, Pfizer.M. Reck: Honorare für Vorträge und Beratungstätigkeiten (Advisory Board) für AstraZeneca, BMS, Boehringer-Ingelheim, Celgene, MSD, Novartis, Pfizer, Roche, Merck.

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center